2023
5′-UTR mRNA splicing determines CD20 levels
MRÁZ, MarekBasic information
Original name
5′-UTR mRNA splicing determines CD20 levels
Authors
MRÁZ, Marek
Edition
2023
Publisher
American Society of Hematology
Other information
Language
English
Type of outcome
Article in a journal (not reviewed)
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
References:
Organization
Středoevropský technologický institut – Repository – Repository
UT WoS
001118816600001
EID Scopus
2-s2.0-85175834117
Keywords in English
chronic lymphocytic leukemia; CD20 messenger RNA; alternative splicing; malignant B cells; anti-CD20 therapies
Links
LX22NPO5102, research and development project.
Changed: 28/3/2024 04:03, RNDr. Daniel Jakubík
Abstract
In the original language
In this issue of Blood, Ang et al(1) show that human CD20 messenger RNA (mRNA) undergoes alternative splicing to generate distinct 5' untranslated region (5'-UTR) variants, which determine the cell-surface CD20 levels in malignant B cells and the interpatient variability in the expression of this therapeutic target. These variants can also be used as an escape mechanism from anti-CD20 therapies.
